Non-Executive Director
Martin is a respected commercial leader with a strong track record in strategy development and operational delivery most recently as Senior Vice President, Rare Diseases at GlaxoSmithKline, where he oversaw the development and launch of Strimvelis, the world’s first life-saving gene therapy for children. He currently serves on the Board of Freeline Therapeutics.